TNF Pharmaceuticals, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000RCTHT3
TNFA
TNF Pharmaceuticals, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
TNF Pharmaceuticals, Inc.
ISIN
US62856X2018
TICKER
TNFA
MIC
XNAS
REUTERS
TNFA.OQ
BLOOMBERG
TNFA US
F&G:
77
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 24.06.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate ...
TNF Pharmaceuticals
Thu, 08.05.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive ...
TNF Pharmaceuticals
Tue, 22.04.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from inte...
TNF Pharmaceuticals
Wed, 16.04.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled “Isomyosamine for the Treatment of Sarcopenia in Older Adults” was delivered by Mitchell...
TNF Pharmaceuticals
Mon, 17.03.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podiu...
TNF Pharmaceuticals
Wed, 05.03.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Ch...
TNF Pharmaceuticals
Tue, 25.02.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treat...
TNF Pharmaceuticals
Wed, 29.01.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosam...
TNF Pharmaceuticals
Wed, 15.01.2025
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) ...
TNF Pharmaceuticals
Thu, 19.12.2024
TNF Pharmaceuticals
US62856X2018
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug iso...
TNF Pharmaceuticals
Information on product placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
